Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Enovis (ENOV) trades at a low multiple relative to its enterprise value and recent revenue traction, creating an asymmetric risk/reward for a mid-term long. The company reported Q2 2025 revenue strength and is launching new reconstructive products, but negative EPS, integration and regulatory complexity, and leadership transition keep valuation com…
The dollar has declined sharply against both the euro and the yuan as officials in Europe and China publicly press for a larger international role for their currencies. Those shifts, combined with investor reassessments of dollar dominance and reports of Chinese regulators nudging domestic holders of U.S. Treasuries, are altering comparative return…
BofA Securities downgraded Sanofi from "buy" to "neutral" and lowered its price objective to €92 from €102, citing a constrained catalyst outlook for 2026-27 and uncertainty following a management transition. The news weighed on the stock, which tumbled more than 6% on Thursday. BofA highlighted a reduced valuation multiple and specific upcoming tr…
The International Energy Agency reports a pullback in global oil supply in January driven by U.S. winter storms, an outage at Kazakhstan's Tengiz field and export constraints in Russia and Venezuela. The IEA now expects 2026 oil output to increase to 108.6 million barrels per day, but forecasts slower demand growth and anticipates a sizeable supply…
U.S. equity futures rose modestly after data showing stronger jobs growth and a lower unemployment rate eased immediate economic concerns. Traders reduced expectations for near-term Federal Reserve rate cuts, shifting odds toward policymakers holding rates steady, while focus turns to Friday's Consumer Price Index for January and a slate of corpora…
Fincantieri updated its 2025 financial outlook and presented a new five-year plan for 2026-2030 at an investor presentation, increasing its 2025 EBITDA margin guidance and setting multi-year revenue and margin targets including projections for 2035. The disclosure was followed by a stock rise of 5.2%.
Syndax (SNDX) has moved from development to commercial execution. Early Revuforj and Niktimvo sales, a recent multi-regional managed access program and a clean technical setup open a high-reward long trade into 2026. The trade balances upside from continued launch momentum against valuation and competition risks.
Citizens reduced its price target on Unity Software (U) to $37.00 from $50.00 while retaining a Market Outperform rating after the company's fourth-quarter 2025 results. Unity beat the high end of its Q4 guidance on both revenue and EBITDA, but gave Q1 2026 guidance that fell below consensus on both measures. Citizens pointed to product and operati…
Citizens reduced its 12-month price target on Vertex Inc. (VERX) to $25 from $37 while keeping a Market Outperform rating, citing concerns about the company's pace of product innovation and the need to accelerate AI adoption internally. The stock trades near its 52-week low amid a steep one-year decline. Recent quarterly results beat modest expecta…
Citizens lowered its price target on Shopify to $160 from $200 while retaining a Market Outperform rating after the company delivered solid fourth-quarter 2025 results. Shopify showed 29% year-over-year GMV growth excluding foreign exchange, GAAP operating margin expansion to 17.2%, and revenue of $11.56 billion over the last twelve months. Analyst…
India's equity benchmarks closed lower on Thursday with the Nifty 50 down 0.57% and the BSE Sensex off 0.66%. Losses concentrated in Technology, Real Estate and Oil & Gas drove the retreat, even as Bajaj Finance, Shriram Finance and Eicher Motors posted gains. Market breadth favoured decliners and the India VIX rose modestly; key commodities and cu…
Citizens has kept its Market Outperform rating on Terawulf Inc. (NASDAQ:WULF) and maintained a $22.00 price target, implying roughly 37% upside from the prevailing share price. The firm pointed to Terawulf's strategy of converting upstate New York sites into hyperscale data centers with lower power costs, recent high-performance computing agreement…
Citizens has reiterated a Market Outperform rating on CoreWeave and assigned a $180 price target, implying roughly 90% upside from the stock's recent price. The firm highlights CoreWeave's leadership in GPU-as-a-Service, sizable revenue backlog and rapid top-line growth while noting risks tied to pricing, customer concentration and leverage. Other …
Citizens lowered its price objective on Pegasystems to $58 from $78 while retaining a Market Outperform rating after the company’s fourth-quarter 2025 results. Pegasystems beat consensus on revenue and non-GAAP EPS, and reported rising annual contract value and stronger-than-expected free cash flow, but a modest slowdown in constant-currency growth…
Citizens has reaffirmed its Market Outperform rating on Applied Blockchain Inc. (APLD) and kept a $40.00 price target, pointing to substantial upside driven by a 4.3GW active development pipeline and fully leased capacity at the North Ellen (Polaris Forge 1) campus. Key leases with CoreWeave and a 200MW agreement with an investment-grade hyperscale…
Citizens has retained its Market Outperform rating on Galaxy Digital (GLXY) and left its $60 price target intact, implying nearly 200% upside from the current share price of $20.39. The firm emphasized Galaxy's expanding position in high-performance computing (HPC) through its Helios campus in West Texas, where an 800MW contract with CoreWeave is s…
Citizens reaffirmed a Market Outperform rating and a $30.00 price target on Fermi Inc. (NASDAQ: FRMI) following a site visit to the company’s planned 11GW data center complex. The target implies more than 215% upside from the current share price of $9.52 and aligns with a bullish analyst consensus with targets between $20 and $37. Citizens highligh…
Citizens reiterated its Market Outperform rating and $400 price target on AeroVironment (NASDAQ:AVAV), citing robust defense funding trends, the strategic BlueHalo merger and growing international opportunities. The firm noted the company’s rapid revenue growth and mass-production experience, while analysts expect profitability and continued sales …
Citizens has reaffirmed a Market Outperform rating on Equinix with a $1,200 price objective after the data center operator released quarterly results. The target implies nearly 40% upside from the current share price of $867.52 even as the stock trades at a high P/E of 78.88. Citizens points to accelerating capacity deployments and an expanding bac…
Goldman Sachs downgraded National Bank of Greece from Buy to Neutral even as it increased its target price to EUR16.75 from EUR15.10. The bank reported a 19.0% CET1 ratio at the end of the third quarter of 2025 and holds around EUR1.9 billion in excess capital, roughly 14% of its market capitalization. Analysts expect the bank to remain profitable …
Micron is trading on strong AI-driven fundamentals: $13.64B in revenue (+56.65% YoY), 56.8% gross margins, and accelerating free cash flow. The market is pricing in continued re-rating as hyperscalers lock in high-bandwidth memory. The trade: enter at $423.20, target $600.00, stop $360.00, mid-term (45 trading days).
Citizens has retained a Market Outperform rating and a $60.00 price target on AtriCure Inc. (NASDAQ: ATRC) ahead of the company’s full fourth-quarter 2025 results. The call follows Edwards Lifesciences’ announcement of plans to introduce a surgical Left Atrial Appendage Closure (LAAC) technology later this year, an update that briefly pushed AtriCu…
Mizuho upgraded Shopify (NASDAQ: SHOP) from Neutral to Outperform while maintaining a $150 price target, highlighting artificial intelligence as a structural tailwind and pointing to strong recent execution. The stock trades near $118.71 after a 6.72% one-week gain but remains down 26.25% year-to-date. Recent fourth-quarter 2025 results beat expect…
Novocure saw a significant premarket share rise after the U.S. Food and Drug Administration approved Optune Pax for use with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer. The device, which administers Tumor Treating Fields, produced modest survival benefits in Phase 3 testing and delayed pain progression, with the approval a…
Raymond James upgraded Oscar Health Inc. from Market Perform to Outperform and set a $18 price target, citing attractive relative valuation and expected margin recovery across the ACA exchange market. The firm projects modest positive EBIT margins in 2026 and further improvement in 2027, even as Oscar reported mixed fourth-quarter financials that f…
